No patents, no generics — first-mover opportunities.
What are uncontested opportunities? These are NDA drugs listed as Reference Listed Drugs (RLDs) in the FDA Orange Book that have no listed patents and no approved generic equivalents. This is the lowest-barrier entry point for generic manufacturers: no patent challenge needed, and the first ANDA filer can earn 180-day marketing exclusivity as the first generic on the market.